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syndrome’ being successfully treated by combined nebulised
and intravenous (IV) therapy with both meropenem and
tobramycin in a 31 year old woman with cystic fibrosis (CF)
and an en-bloc liver–pancreas transplant [1]. This reminded us
of one of our current patients who survived the ‘cepacia
syndrome’ following treatment with IV antibiotics, nebulised
tobramycin and recombinant human deoxyribonuclease
(rhDNase) and remains relatively well 8 years later.
A female (ΔF508 homozygote) was diagnosed in 1991 at
6 weeks of age by New Zealand's newborn CF screening
programme. By 8 years of age, other than for a chronic cough,
she had been well with good growth, stable lung function
(forced expiratory volume in 1 s (FEV1) % predicted values
N100%) and no previous hospitalisations. Her usual medica-
tions included inhaled corticosteroids, pancreatic enzymes and
fat soluble vitamin supplements, but no regular antibiotics.
In July, 1999 she was hospitalised with a one day history of
fever, worsening cough and chest pain. She appeared non-toxic,
temperature was 38.9 °C, pulse 120/min, respiration 36/min,
while moderate digital clubbing, mild chest wall recession and
percussion dullness over the apex of the right lung were noted. A⁎ Corresponding author. Queensland Paediatric Infectious Diseases Laboratory,
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in the right upper lobe. The peripheral white blood cell count was
21.3×109/L, C-reactive protein (CRP) 146 mg/L, a Mantoux test
was negative and neutrophil dihydrorhodamine oxidation was
normal. The sputum grewmethicillin-susceptible Staphylococcus
aureus. She responded promptly to 2 weeks of IV flucoxacillin
and gentamicin by which time her fever, clinical signs and
haematological and inflammatory indices normalised. After-
wards, she received oral flucloxacillin for 3 months and by then
the cough had resolved and the chest X-ray showed only a small
cystic space at the right apex.
During the next 9 months her cough reappeared, no weight
gains were recorded and oral amoxicillin-clavulanate was
prescribed for S. aureus and Haemophilus influenzae in the
sputum. In June 2000, when aged 9 years, she was hospitalised
following 10 days of fever, malaise and deteriorating cough. Her
temperature was 37.8 °C, pulse 120/min, respiration 30/min, and
auscultatory crackles were heard over the right lung apex. A chest
X-ray revealed bilateral upper lobe nodular infiltrates. Her FEV1
had declined from 101% to 44% predicted, the white blood cell
count was 6.6×109/L, CRP 86 mg/L and blood cultures were
sterile. Sputum was unobtainable, whereupon bronchoalveolar
lavage was performed and an organism belonging to the Bur-
kholderia cepacia complex was grown from all 5 lung lobes. The
isolate was subsequently confirmed as B. cenocepacia, clade A
[2], and it was resistant to all β-lactams, aminoglycosides,
fluoroquinolones, trimethoprim-sulphamethoxazole, colistin,
doxycycline and chloramphenicol.
While awaiting multiple combination bactericidal antibiotic
test results, both IV meropenem and ceftazidime were
administered. This was the simplest antibiotic combinationd by Elsevier B.V. All rights reserved.
Fig. 1. Computed tomographic scan demonstrating a multiloculated abscess
cavity in the posterior portion of the left upper lobe. Other slices (not shown)
demonstrated a smaller single cavity in the right upper lobe and bronchial wall
thickening and bronchiectasis involving all other lobes.
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activity against panresistant B. cepacia complex organisms [3].
Unfortunately, this combination did not prove bactericidal.
Although the FEV1 increased to 69%, for the next 6 weeks
intermittent fevers, cough and auscultatory crackles persisted.
Moreover, a chest X-ray and CT scan (Fig. 1) showed that two
abscess cavities had formed in both upper lobes. Based upon the
clinical picture and the multiple combination antibiotic
susceptibility test results, treatment was changed to a bacter-
icidal combination of IV ceftazidime, tobramycin and trimetho-
prim-sulphamethoxazole. Within 2 weeks the fever and cough
resolved, her weight increased 2 kg, the FEV1 improved to 83%
predicted and her inflammatory markers normalised.
After an initial improvement, the next 6 months were marked
by recurrent fevers, static weight gains, persistent dry cough, a
peak FEV1 of 94% predicted and reduced size of the abscess
cavities, but increased reticulonodular shadowing throughout
both lung fields and persistence of B. cenocepacia in her
sputum. During this period, she was hospitalised on four
occasions for intensive treatment, including IV antibiotics, but
by March 2001, the frequency and duration of hospitalisationTable 1
Selected characteristics of cases surviving ‘cepacia syndrome’.
Case Age Sex Prior
pathogens
B. cepacia sp Blood Sputum/
BAL
Pneum
1 11y F S. aureus B. cenocepacia + + +
P. aeruginosa
2 31y F P. aeruginosa B. cenocepacia + +
3 10y F S. aureus B. cenocepacia + + +
H. influenzae
ceftaz, ceftazidime; chloram, chloramphenicol; cipro, ciprofloxacin; mero, meropen
tobramycin for inhalation; tobra, tobramycin; TMP-SMX, trimethoprim-sulphamethwere both increasing. At this time, 5 days immediately after a
3 week period in hospital, she was readmitted with fever,
malaise and worsening cough. Her temperature was 39 °C,
pulse 130/min, respiration 30/min, oxygen saturation of 88% in
air, and widespread auscultatory crackles were heard. The FEV1
had deteriorated to 44% predicted, the white blood cell count
was 14.1×109/L, CRP 113 mg/L and a chest X-ray showed
increased consolidation in the lower lobes as well as the
aforementioned upper lobe cavities. IV ceftazidime, tobramycin
and trimethoprim-sulphamethoxazole were reinstituted, but she
remained febrile, requiring 60% fractional inspired oxygen.
Two repeat blood cultures taken 5 days after introducing triple
antibiotics and when she appeared septic grew B. cenocepacia
within 12 h of inoculation. Subsequent genomic finger printing
with pulse field gel electrophoresis demonstrated blood and
respiratory isolates to be indistinguishable from one another.
Based upon the then recent experience of the Toronto
transplant programme where more aggressive antimicrobial
therapy improved survival of CF lung transplant patients
infected with B. cepacia complex [4], we added nebulised
tobramycin (160 mg daily). rhDNase (2.5 mg daily) was also
introduced because of its mucolytic properties. Over the next
week her fever settled and within two weeks supplemental
oxygen was discontinued. When discharged home after
5 weeks, her physical signs and inflammatory markers had
resolved and she was taking only nebulised rhDNase.
Since then B. cenocepacia remains in her sputum and every
3 months she is admitted to hospital for IVantibiotics, nebulised
tobramycin and physical therapy. An attempt in January 2002
to stop rhDNase when she was clinically stable was unsuccess-
ful. This resulted 10 days later in an acute hospital admission
with fever, cough, reappearance of auscultatory crackles and an
elevated CRP of 83 mg/L. At the time there was no epidemi-
ological or laboratory evidence of an intercurrent respiratory
infection and she rapidly recovered with IV antibiotics and
reintroduction of rhDNase.
A repeat CT scan in December 2002 showed only small
nodular opacities where previously abscess cavities existed,
accompanied by mild bronchial wall thickening and dilatation in
the mid zones of both lungs. Now, 8 years after the ‘cepacia
syndrome’, she is almost 18 years old, growing and developing
normally, still using rhDNase and coping well at University. In
2006 she developed CF-related diabetes and a year later beganonia IV antibiotics Additional Rx Outcome Ref
ceftaz/mero/cipro/
chloram/TMP-SMX
IV methyl-prednisilone Alive after
5 months
[9]
mero/tobra/TMP-
SMX/temocillin
Nebulised mero+ tobra
(TOBI)
Alive after
16 months
[1]
ceftaz/tobra/
TMP-SMX
Nebulised tobra+
rhDNase
Alive after
8 yrs
Current
em; rhDNase, recombinant human deoxyribonuclease; TOBI, preservative free
asoxazole.
293Successful treatment of cepacia syndromeazithromycin for gradually deteriorating lung function where best
FEV1 values fell from N90% in 2001 to 68% predicted by 2008.
The clinical outcome in CF patients of infection by B. cepacia
complex is unpredictable and probably influenced by host–
pathogen interactions rather than solely by microbial virulence
factors [5]. While most CF patients harbouring B. cenocepacia
are chronically infectedwith relatively stable pulmonary function,
some develop a rapidly progressive necrotising pneumonia. The
latter is known as the ‘cepacia syndrome’, which in its preterminal
phase is often accompanied by bacteraemia with death resulting
from sepsis and respiratory failure [1,6,7]. Nevertheless, two
virulence properties seem important for this condition to develop
[8]. The first is an ability of the organism to invade and survive
within the lungs and circulation and the second is to induce an
exaggerated, but ineffective, cellular immune response.
To our knowledge, this is the third published case to survive
‘cepacia syndrome’ (Table 1). All patients deteriorated on
conventional high-dose IV antibiotics until corticosteroids or
nebulised treatments were introduced. The mechanisms for these
patients surviving remain uncertain. In our patient early treatment
was guided bymultiple combination bactericidal antibiotic testing
of planktonically growing bacteria. However, a recent rando-
mised controlled trial failed to show a clinical benefit for patients
receiving therapy directed by combination antibiotic suscept-
ibility testing [10]. Indeed, when isolates from this study were re-
tested under biofilm conditions similar to that believed to exist
within the CF lung, only a minority remained susceptible to the
antibiotic combinations [11]. Interestingly, patients receiving
therapy effective against organisms growing in biofilms seem to
have better clinical outcomes. We were unable to perform biofilm
susceptibility testing on the patient's isolate, but it is possible that
addition of nebulised tobramycin enhanced antibacterial activity
within her lungs and helped to control the infection. The role of
rhDNase during acute pulmonary exacerbations in CF is
unproven [12]. Perhaps in our patient, by acting as a mucolytic
agent and breaking down polymerised DNA, it led to improved
bioavailability for the inhaled tobramycin. It may also have
provided an indirect anti-inflammatory effect from improved
clearance of retained secretions [13]. Whatever the mechanisms
involved, until we gain further understanding of this group of
organisms, clinicians now have additional options for treating‘cepacia syndrome’, which previously has been a fatal complica-
tion of certain B. cepacia complex infections.
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